XML 70 R53.htm IDEA: XBRL DOCUMENT
v3.20.1

Segments of Business (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2020
Segment Reporting [Abstract] |
Schedule of segment information | Financial information relating to the Company’s reportable operating segments and reconciliations to the consolidated totals is as follows:
| Years Ended March 31,
(In millions) | 2020 |  | 2019 |  | 2018
Revenues |  |  |  |  |
U.S. Pharmaceutical and Specialty Solutions (1) | $ | 183,341 |  |  | $ | 167,763 |  |  | $ | 162,587 |
European Pharmaceutical Solutions (1) | 27,390 |  |  | 27,242 |  |  | 27,320 |
Medical-Surgical Solutions (1) | 8,305 |  |  | 7,618 |  |  | 6,611 |
Other | 12,015 |  |  | 11,696 |  |  | 11,839 |
Total Revenues | $ | 231,051 |  |  | $ | 214,319 |  |  | $ | 208,357 |
Operating profit (loss) (2) |  |  |  |  |
U.S. Pharmaceutical and Specialty Solutions (3) | $ | 2,767 |  |  | $ | 2,697 |  |  | $ | 2,535 |
European Pharmaceutical Solutions (4) | (261 | ) |  | (1,978 | ) |  | (1,681 | )
Medical-Surgical Solutions | 499 |  |  | 455 |  |  | 461 |
Other (5) (6) (7) (8) | (595 | ) |  | 394 |  |  | (107 | )
Total | 2,410 |  |  | 1,568 |  |  | 1,208 |
Corporate Expenses, Net (9) | (1,017 | ) |  | (694 | ) |  | (564 | )
Loss on Debt Extinguishment | — |  |  | — |  |  | (122 | )
Interest Expense | (249 | ) |  | (264 | ) |  | (283 | )
Income from Continuing Operations Before Income Taxes | $ | 1,144 |  |  | $ | 610 |  |  | $ | 239 |
Depreciation and amortization (10) |  |  |  |  |
U.S. Pharmaceutical and Specialty Solutions | $ | 228 |  |  | $ | 238 |  |  | $ | 210 |
European Pharmaceutical Solutions | 235 |  |  | 257 |  |  | 296 |
Medical-Surgical Solutions | 136 |  |  | 118 |  |  | 97 |
Other | 187 |  |  | 214 |  |  | 237 |
Corporate | 136 |  |  | 122 |  |  | 111 |
Total | $ | 922 |  |  | $ | 949 |  |  | $ | 951 |
Expenditures for long-lived assets (11) |  |  |  |  |
U.S. Pharmaceutical and Specialty Solutions | $ | 94 |  |  | $ | 88 |  |  | $ | 126 |
European Pharmaceutical Solutions | 95 |  |  | 85 |  |  | 104 |
Medical-Surgical Solutions | 36 |  |  | 110 |  |  | 34 |
Other | 61 |  |  | 68 |  |  | 42 |
Corporate | 76 |  |  | 75 |  |  | 99 |
Total | $ | 362 |  |  | $ | 426 |  |  | $ | 405 |
Revenues, net by geographic area |  |  |  |  |  |  |  |
United States | $ | 192,709 |  |  | $ | 176,296 |  |  | $ | 169,943 |
Foreign | 38,342 |  |  | 38,023 |  |  | 38,414 |
Total Revenues | $ | 231,051 |  |  | $ | 214,319 |  |  | $ | 208,357 |
(1) | Revenues from services represent less than 1% of the Company’s U.S. Pharmaceutical and Specialty Solutions segment’s total revenues, less than 10% of the Company’s European Pharmaceutical Solutions segment’s total revenues and less than 2% of the Company’s Medical-Surgical Solutions segment’s total revenues.
(2) | Segment operating profit (loss) includes gross profit, net of operating expenses, as well as other income (expense), net, for the Company’s operating segments.
(3) | The Company’s U.S. Pharmaceutical and Specialty Solutions segment’s operating profit for 2020, 2019 and 2018 includes pre-tax credits of $252 million, $210 million and $99 million ($186 million, $156 million and $64 million after-tax) related to the LIFO method of accounting for inventories. Operating profit for 2020, 2019 and 2018 also includes $22 million, $202 million and $144 million of cash receipts for the Company’s share of antitrust legal settlements. In addition, operating profit for 2019 includes a pre-tax charge of $61 million ($45 million after-tax) related to a customer bankruptcy and 2018 includes a pre-tax gain of $43 million ($26 million after-tax) from the sale of an equity investment.
(4) | European Pharmaceutical Solutions segment’s operating loss for 2020 includes a charge of $275 million (pre-tax and after-tax) to remeasure to fair value the assets and liabilities of the Company’s German wholesale business to be contributed to a joint venture, and for 2020, 2019 and 2018 also includes pre-tax long-lived asset impairment charges of $82 million, $210 million and $446 million ($66 million, $172 million and $410 million after-tax). Operating loss for 2019 and 2018 includes pre-tax goodwill impairment charges of $1.8 billion and $1.3 billion (pre-tax and after-tax).
(5) | Operating loss for Other for 2020 includes a pre-tax impairment charge of $1.2 billion ($864 million after-tax) and a pre-tax dilution loss of $246 million ($184 million after-tax) associated with the Company’s investment in the Change Healthcare JV, along with an estimated gain of $414 million (pre-tax and after-tax) related to the split-off of the Change Healthcare JV.
(6) | Operating profit (loss) for Other for 2020, 2019 and 2018 includes pre-tax goodwill and long-lived asset impairment charges of $32 million, $56 million and $488 million (pre-tax and after-tax) recognized for the Company’s Rexall Health retail business. The 2019 operating profit for Other also includes a pre-tax gain from an escrow settlement of $97 million (pre-tax and after-tax) representing certain indemnity and other claims related to the Company’s 2017 acquisition of Rexall Health. In addition, operating profit for 2019 includes pre-tax restructuring and asset impairment charges of $91 million ($86 million after-tax), primarily associated with lease and other exit-related costs and a pre-tax gain of $56 million ($41 million after-tax) recognized from the sale of an equity investment.
(7) | Operating profit for Other for 2019 includes a pre-tax credit of $90 million ($66 million after-tax) for the derecognition of the TRA liability payable to the shareholders of Change. Operating profit (loss) for Other also includes the Company’s proportionate share of loss from the Change Healthcare JV of $119 million, $194 million and $248 million for 2020, 2019 and 2018.
(8) | Operating loss for Other for 2018 includes a pre-tax gain of $109 million ($30 million after-tax) from the sale of the Company’s EIS business and a pre-tax credit of $46 million ($30 million after-tax) representing a reduction in its TRA liability.
(9) | Corporate expenses, net, for 2020 include pre-tax settlement charges of $122 million ($90 million after-tax) for the termination of the Company’s defined benefit pension plan and a settlement charge of $82 million ($61 million after-tax) related to opioid claims. Corporate expenses, net, for 2019 include pre-tax restructuring and asset impairment charges of $94 million ($70 million after-tax) primarily associated with employee severance and other exit-related costs.
(10) | Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use.
(11) Long-lived assets consist of property, plant and equipment.
Schedule of segment assets and property, plant and equipment, net by geographic areas | Segment assets and property, plant and equipment, net by geographic areas were as follows:
| March 31,
(In millions) | 2020 |  | 2019
Segment assets |  |  |
U.S. Pharmaceutical and Specialty Solutions | $ | 34,927 |  |  | $ | 32,310 |
European Pharmaceutical Solutions | 9,499 |  |  | 7,829 |
Medical-Surgical Solutions | 5,395 |  |  | 5,260 |
Other | 7,944 |  |  | 11,006 |
Corporate | 3,482 |  |  | 3,267 |
Total | $ | 61,247 |  |  | $ | 59,672 |
Property, plant and equipment, net |  |  |  |  |
United States | $ | 1,642 |  |  | $ | 1,698 |
Foreign | 723 |  |  | 850 |
Total | $ | 2,365 |  |  | $ | 2,548 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration